Preface vii

Chapter 1
Type 2 diabetes: rationale for pharmacological treatment 1
1. Introduction 1
2. Type 2 diabetes: a progressive disorder 5
3. Pathophysiology 7
4. Safety of intensive glucose-lowering strategies in high-risk patients 11
5. Therapeutic approaches 17
6. Guidelines and treatment algorithms 19

Chapter 2
Established classes of glucose-lowering drugs 27
1. Introduction 27
2. Biguanides 28
3. Sulphonylureas 32
4. Meglitinides 36
5. Thiazolidinediones 38
6. Alpha-glucosidase inhibitors 47
7. Fixed dose combinations of orally active drugs 50
8. Principles of insulin therapy in type 2 diabetes 50
9. Weight-reducing drugs 59

Chapter 3
Recently introduced and emerging classes of glucose-lowering drugs 63
1. Drugs acting on the incretin system 63
2. Pathophysiology of the incretin system in type 2 diabetes 63
3. Dipeptidyl peptidase 4 inhibitors 65
4. Glucagon-like peptide 1 agonists 71
5. Amylin analogues 78
6. Bromocriptine 79
7. Drugs in development 80

Chapter 4
The place of newer drugs in treatment algorithms 83
1. Recommended management of type 2 diabetes 83
2. Current NICE guidance: oral glucose-lowering drugs 84
3. NICE guidance: injectable agents 88
4. National and international guidelines compared 89

Index 97
Drug Therapy for Type 2 Diabetes
Krentz, A.
2012, VII, 102 p. 20 illus. in color., Softcover
ISBN: 978-1-908517-64-7